Figures & data
Table 1 Demographic data of the generic escitalopram (Lexacure®) and branded escitalopram (Lexapro®) groups (ITT)
Figure 1 Changes in MADRS, HDRS, and CGI-S from baseline to week 6 (PP).
Abbreviations: CGI-S, Clinical Global Impressions-Severity scale; HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; PP, per protocol.
![Figure 1 Changes in MADRS, HDRS, and CGI-S from baseline to week 6 (PP).](/cms/asset/d4f1f1dd-e2f6-4565-a05e-3e1822623531/dndt_a_90796_f0001_b.jpg)
Table 2 Changes in MADRS scores and comparisons of the generic escitalopram (Lexacure®) and branded escitalopram (Lexapro®) groups at each study visit (PP)
Figure 2 Comparisons of response and remission rates between the generic escitalopram (Lexacure®) and branded escitalopram (Lexapro®) groups (PP).
Abbreviations: CGI-I, Clinical Global Impressions–Improvement scale; HDRS, Hamilton Depression Rating Scale; PP, per protocol; MADRS, Montgomery–Åsberg Depression Rating Scale.
![Figure 2 Comparisons of response and remission rates between the generic escitalopram (Lexacure®) and branded escitalopram (Lexapro®) groups (PP).](/cms/asset/6a97b846-3a1e-460c-aa83-c86ef58569df/dndt_a_90796_f0002_b.jpg)
Table 3 The presence of adverse events in the generic escita-lopram (Lexacure®) and branded escitalopram (Lexapro®) groups (AEs >1.0%; ITT)